We provide you with 20 years of free, institutional-grade data for ALLK stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ALLK. Explore the full financial landscape of ALLK stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Radford Harlan Baird | Sale | -87,064 | $1.01 | $87,935 | 2024-07-02 |
| Alexander Robert | Sale | -37,525 | $1.14 | $42,778 | 2024-06-10 |
| Tomasi Adam | Sale | -24,749 | $1.12 | $27,719 | 2024-06-10 |
| Radford Harlan Baird | Sale | -14,565 | $1.19 | $17,332 | 2024-06-06 |
| Radford Harlan Baird | Sale | -32,142 | $1.35 | $43,392 | 2024-03-07 |
| Tomasi Adam | Sale | -47,392 | $1.44 | $68,244 | 2024-03-06 |
| Alexander Robert | Sale | -70,910 | $1.48 | $104,947 | 2024-03-06 |
| Lee Chin Hyok | Initial | 2024-02-16 | |||
| BVF PARTNERS L P/IL | Initial | 2024-01-26 | |||
| Radford Harlan Baird | Sale | -8,380 | $2.5 | $20,950 | 2023-12-05 |
| Alexander Robert | Sale | -24,753 | $2.5 | $61,883 | 2023-12-05 |
| Paterson Craig A. | Sale | -6,992 | $2.5 | $17,480 | 2023-12-05 |
| Tomasi Adam | Sale | -16,054 | $2.5 | $40,135 | 2023-12-05 |
| Tomasi Adam | Sale | -18,219 | $3.01 | $54,839 | 2023-09-07 |
| Paterson Craig A. | Sale | -7,935 | $3.01 | $23,884 | 2023-09-07 |
| Radford Harlan Baird | Sale | -9,511 | $3.01 | $28,628 | 2023-09-07 |
| Alexander Robert | Sale | -28,096 | $3.01 | $84,569 | 2023-09-07 |
| Radford Harlan Baird | Sale | -8,942 | $5.13 | $45,872 | 2023-06-05 |
| Alexander Robert | Sale | -26,415 | $5.13 | $135,509 | 2023-06-05 |
| Tomasi Adam | Sale | -17,129 | $5.13 | $87,872 | 2023-06-05 |
| Paterson Craig A. | Sale | -7,460 | $5.13 | $38,270 | 2023-06-05 |
| Alexander Robert | Sale | -75,417 | $6.4 | $482,669 | 2023-03-09 |
| Tomasi Adam | Sale | -57,467 | $5.34 | $306,874 | 2023-03-08 |
| Radford Harlan Baird | Sale | -33,907 | $5.75 | $194,965 | 2023-03-06 |
| Paterson Craig A. | Sale | -26,615 | $5.83 | $155,165 | 2023-03-06 |
| Radford Harlan Baird | Grant, award...etc | 126,640 | 2023-01-09 | ||
| Paterson Craig A. | Grant, award...etc | 102,690 | 2023-01-09 | ||
| Tomasi Adam | Grant, award...etc | 195,997 | 2023-01-09 | ||
| Alexander Robert | Grant, award...etc | 301,575 | 2023-01-09 | ||
| Tomasi Adam | Sale | -9,783 | $8.11 | $79,340 | 2022-12-05 |
| Paterson Craig A. | Sale | -4,863 | $8.11 | $39,439 | 2022-12-05 |
| Radford Harlan Baird | Sale | -3,843 | $8.11 | $31,167 | 2022-12-05 |
| Alexander Robert | Sale | -15,152 | $8.11 | $122,883 | 2022-12-05 |
| Walker Paul Edward | Open Market Purchase | 3,386,400 | $5.02 | 2022-09-23 | |
| Walker Paul Edward | Open Market Purchase | 597,600 | $5.02 | 2022-09-23 | |
| JANNEY DANIEL | Open Market Purchase | 475,000 | $5.02 | 2022-09-23 | |
| Fitzgerald Margaret Nell | Sale | -335 | $4.54 | $1,521 | 2022-09-06 |
| Paterson Craig A. | Sale | -1,129 | $4.54 | $5,126 | 2022-09-06 |
| Radford Harlan Baird | Sale | -585 | $4.54 | $2,656 | 2022-09-06 |
| Tomasi Adam | Sale | -5,369 | $4.54 | $24,375 | 2022-09-06 |
| Alexander Robert | Sale | -8,316 | $4.54 | $37,755 | 2022-09-06 |
| Fitzgerald Margaret Nell | Sale | -318 | $2.75 | $875 | 2022-06-03 |
| Tomasi Adam | Sale | -5,219 | $2.75 | $14,352 | 2022-06-03 |
| Alexander Robert | Sale | -8,084 | $2.75 | $22,231 | 2022-06-03 |
| Paterson Craig A. | Sale | -226 | $2.75 | $622 | 2022-06-03 |
| Radford Harlan Baird | Sale | -2,274 | $2.75 | $6,254 | 2022-06-03 |
| Paterson Craig A. | Initial | 2022-05-11 | |||
| Fitzgerald Margaret Nell | Initial | 2022-05-04 | |||
| Fitzgerald Margaret Nell | Grant, award...etc | 57,637 | 2022-05-04 | ||
| Asbury Mark | Sale | -1,680 | $5.38 | $9,038 | 2022-03-03 |
| Tomasi Adam | Sale | -5,582 | $5.38 | $30,031 | 2022-03-03 |
| Alexander Robert | Sale | -8,215 | $5.38 | $44,197 | 2022-03-03 |
| Alexander Robert | Grant, award...etc | 529,323 | 2022-03-01 | ||
| Asbury Mark | Grant, award...etc | 140,490 | 2022-03-01 | ||
| Tomasi Adam | Grant, award...etc | 344,060 | 2022-03-01 | ||
| Radford Harlan Baird | Grant, award...etc | 237,608 | 2022-03-01 |
The information provided in this report about ALLK stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Allakos Inc(NASDAQ:ALLK) 
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic es...
Website: http://www.allakos.com
Founded: 2012
Full Time Employees: 114
CEO: Robert D. Alexander Ph.D.
Sector: Healthcare
Industry: Biotechnology